Self-assembled DNA nanoparticles loaded with Travoprost for Glaucoma-treatment
Publication date: Available online 3 July 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Sven Schnichels, José Hurst, Jan Willem de Vries, Sami Ullah, Agnieszka Gruszka, Minseok Kwak, Marina Löscher, Sascha Dammeier, Karl-Ulrich Bartz-Schmidt, Martin S Spitzer, Andreas Herrmann (Source: Nanomedicine: Nanotechnology, Biology and Medicine)
Source: Nanomedicine: Nanotechnology, Biology and Medicine - July 4, 2020 Category: Nanotechnology Source Type: research
Effectiveness of Blepharoptosis Surgery in Patients With Deepening of the Upper Eyelid Sulcus
The purpose of this retrospective study was to evaluate the effectiveness of blepharoptosis surgery in patients with deepening of the upper eyelid sulcus (DUES). This case series included 10 consecutive patients (19 eyes) with DUES associated with use of a prostaglandin analog for glaucoma. Patients who had used bimatoprost and developed DUES were changed to an alternative prostaglandin analog and observed for ≥3 months. If there was no improvement, they underwent levator resection for blepharoptosis and were followed up for ≥6 months postoperatively. Improvement in margin reflex distance-1 and surgical complications w...
Source: Journal of Craniofacial Surgery - July 1, 2020 Category: Surgery Tags: Original Articles Source Type: research
Durysta - A Bimatoprost Implant for Glaucoma
Date: July 27, 2020
Issue #:
1603Summary:
The FDA has approved an intracameral implant
containing the prostaglandin analog bimatoprost
(Durysta– Allergan) for reduction of intraocular
pressure (IOP) in patients with open-angle glaucoma
or ocular hypertension. Bimatoprost is also
available in 0.01%(Lumigan) and 0.03% (generics)
ophthalmic solutions for the same indication and in
a 0.03% solution(Latisse, and generics) for eyelash
enhancement.Durysta is the first ocular implant to
become available in the US for treatment of glaucoma. (Source: The Medical Letter)
Source: The Medical Letter - June 23, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Bimatoprost Durysta Eye glaucoma Latanoprost latanoprostene bunod Latisse Lumigan netarsudil Rhopressa tafluprost Travatan Z travoprost Vistitan Vyzulta Xalatan Xelpros Zioptan Source Type: research
Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: improved pharmacokinetic/pharmacodynamic properties
Publication date: Available online 5 May 2020Source: International Journal of PharmaceuticsAuthor(s): Ayman Ismail, Maha Nasr, Omaima Sammour (Source: International Journal of Pharmaceutics)
Source: International Journal of Pharmaceutics - May 6, 2020 Category: Drugs & Pharmacology Source Type: research
Toxicity profiles of fixed-combination eye drops for glaucoma therapy using cultivated human corneal epithelial sheets
ConclusionGlaucoma fixed-combination eye drops demonstrated a different toxic effect on the cell viability, barrier function, and morphologic changes of HCES. (Source: Japanese Journal of Ophthalmology)
Source: Japanese Journal of Ophthalmology - April 26, 2020 Category: Opthalmology Source Type: research
Changes in Prostaglandin-associated Periorbital Syndrome After Switch from Conventional Prostaglandin F2α Treatment to Omidenepag Isopropyl in 11 Consecutive Patients
Conclusions:
Some PAPS signs improved after patients started taking omidenepag isopropyl. Our findings will be useful for patients taking antiglaucoma eye drops. (Source: Journal of Glaucoma)
Source: Journal of Glaucoma - April 1, 2020 Category: Opthalmology Tags: Case Report/Small Case Series Source Type: research
A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients
ConclusionThe efficacy and safety of glaucoma medications were assessed by NMA as reference to those of timolol maleate 0.5% in Japanese patients. PG analogs were the most efficacious in reducing IOP. However, PG analogs were also associated with higher rates of adverse reactions and conjunctival hyperemia. (Source: Japanese Journal of Ophthalmology)
Source: Japanese Journal of Ophthalmology - February 23, 2020 Category: Opthalmology Source Type: research
Effects of a prostaglandin F2alpha derivative glaucoma drug on EGF expression and E-cadherin expression in a corneal epithelial cell line.
Conclusions: Travoprost activates epithelial cell proliferation by up-regulating an EGF-related signal in association with the suppression of E-cadherin localization in the cell-cell contact zone. Modulation of the EGF signal may be a strategy to minimize the negative impact of this mitogen on reformation of corneal barrier function during epithelial renewal.
PMID: 31986917 [PubMed - as supplied by publisher] (Source: Cutaneous and Ocular Toxicology)
Source: Cutaneous and Ocular Toxicology - January 26, 2020 Category: Toxicology Authors: Takada Y, Yamanaka O, Okada Y, Sumioka T, Reinach PS, Saika S Tags: Cutan Ocul Toxicol Source Type: research
Reply to Comment on: Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase After Cataract Surgery in Eyes With Glaucoma
Dr Özcura raised several questions regarding our article on the effect of topical hypotensive medications to prevent an increase in intraocular pressure (IOP) after cataract surgery in eyes with glaucoma.1 Our study revealed that, compared with travoprost or timolol, brinzolamide administered to eyes with glaucoma immediately after phacoemulsification more effectively decreases the short-term IOP increase. We would like to address the questions raised by Dr Özcura. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - December 8, 2019 Category: Opthalmology Authors: Ken Hayashi, Motoaki Yoshida, Tatsuhiko Sato, Shin-ichi Manabe Tags: Correspondence Source Type: research
Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase After Cataract Surgery in Eyes With Glaucoma
Dr Özcura raised several questions regarding our article on the effect of topical hypotensive medications to prevent an increase in intraocular pressure (IOP) after cataract surgery in eyes with glaucoma.1 Our study revealed that, compared with travoprost or timolol, brinzolamide administered to eyes with glaucoma immediately after phacoemulsification more effectively decreases the short-term IOP increase. We would like to address the questions raised by Dr Özcura. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - December 8, 2019 Category: Opthalmology Authors: Ken Hayashi, Motoaki Yoshida, Tatsuhiko Sato, Shin-ichi Manabe Tags: Correspondence Source Type: research
Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
ConclusionsThe travoprost metabolite 15-keto fluprostenol was effective in decrease IOP and maintained IOP reduction along 5 days of treatment. The 15-keto fluprostenol can be developed as a good candidate for once-a-day NTG patients’ treatment. (Source: International Ophthalmology)
Source: International Ophthalmology - December 2, 2019 Category: Opthalmology Source Type: research
Effect of 6-week washout period on intraocular pressure following chronic prostaglandin analogue treatment: a randomized controlled trial.
CONCLUSIONS: Six weeks of PGA washout after long-term monotherapy resulted in a small but statistically significant IOP increase. Majority of washout group participants maintained an IOP lower than 21 mm Hg after the 6-week washout duration. (https://clinicaltrials.gov/ identifier, NCT03534882).
PMID: 31712013 [PubMed - as supplied by publisher] (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - November 6, 2019 Category: Opthalmology Authors: Lim CW, Diaconita V, Liu E, Ault N, Lizotte D, Nguyen M, Hutnik CML Tags: Can J Ophthalmol Source Type: research
Evaluation of Contrast sensitivity after four different treatment modalities using optec-functional vision analyzer in primary open-angle glaucoma
CONCLUSION: Our study showed that CS values at low and high spatial frequencies after applying timolol and brimonidine eye drops are temporarily reduced in patients with POAG. (Source: Middle East African Journal of Ophthalmology)
Source: Middle East African Journal of Ophthalmology - August 25, 2019 Category: Opthalmology Authors: Parvin Azizzadeh Masoud Safarzadeh Source Type: research
Comment on: Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma
We read with great interest the randomized controlled trial evaluating the prophylactic effect of the classes of topical intraocular pressure (IOP) –lowering medication for preventing IOP increase after cataract surgery in eyes with glaucoma.1 Hayashi and associates1 found that the mean IOP and incidence of IOP spikes were significantly lower in patients who were given postoperative brinzolamide compared with travoprost or timolol. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - August 1, 2019 Category: Opthalmology Authors: Arij Daas, Henrietta Ho, Kin Sheng Lim Tags: Correspondence Source Type: research
Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: A meta-analysis
Conclusions:
0.03% bimatoprost appears more effective following long time use (3 and 6 month post-treatment) for IOP control compared to 0.005% latanoprost, and is more effective compared to 0.004% travoprost after being used for a certain period of time (3 months post-treatment); nevertheless, 0.005% latanoprost is better tolerated in patients with POAG or OHT. (Source: Medicine)
Source: Medicine - July 1, 2019 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research
